David Kuter, MD
Hematology · Boston, MANPI 1457342024
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $369,880 of the $542,910 with a category attached, or 68.1%. It is spread thinly across 31 manufacturers, the largest accounting for just 23.2%. Among hematology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 272 payments — averaging $1995.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$126K
- Sanofi$110K
- Novartis$75K
- Swedish Orphan Biovitrum AB$55K
- AstraZeneca$38K
- Dova Pharmaceuticals$27K
- plus $113K from 25 others
Across 324 payments — averaging $8825.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$950K
- Agios Pharmaceuticals, Inc.$460K
- Sanofi US Services Inc.$380K
- Rigel Pharmaceuticals, Inc.$324K
- Sanofi$160K
- Bioverativ Therapeutics Inc.$150K
- plus $437K from 10 others
What the payments were for
- Consulting fees$369,88068%
- Speaking & faculty fees$83,83315%
- Travel & lodging$84,92216%
- Food & beverage$4,2321%
- Education$420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 54 | $125,813 |
| Sanofi | 40 | $109,709 |
| Novartis | 37 | $75,305 |
| Swedish Orphan Biovitrum AB | 13 | $54,588 |
| AstraZeneca | 30 | $37,543 |
| Dova Pharmaceuticals | 12 | $26,547 |
| UCB SA | 8 | $20,930 |
| Merck | 20 | $14,139 |
| Sobi, Inc | 7 | $9,331 |
| Chugai Pharmaceutical Co., Ltd. | 6 | $8,430 |
| Biocryst Pharmaceuticals, Inc. | 5 | $8,215 |
| Rigel Pharmaceuticals, Inc. | 7 | $7,243 |
| Novartis Pharma AG | 1 | $5,502 |
| UCB, Inc. | 1 | $4,830 |
| Apellis Pharmaceuticals, Inc. | 3 | $4,607 |
| Sanofi US Services Inc. | 1 | $4,512 |
| Pfizer | 3 | $4,500 |
| Vertex | 2 | $4,270 |
| Bioverativ Therapeutics Inc. | 3 | $3,165 |
| Incyte Corporation | 1 | $2,460 |
| Recordati_rare_diseases_inc. | 2 | $2,397 |
| Alnylam Pharmaceuticals Inc. | 1 | $2,223 |
| E.r. Squibb & Sons, L.L.C. | 6 | $1,767 |
| Daiichi Sankyo Inc. | 1 | $1,290 |
| New York Blood Center, Inc. | 1 | $1,200 |
| Regeneron | 1 | $881 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $784 |
| Ipsen Bioscience Inc. | 1 | $580 |
| Argenx US, Inc. | 1 | $108 |
| Agios Pharmaceuticals, Inc. | 1 | $21 |
| UCB Biosciences Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$542,910 in reported general payments places this provider in the 95th percentile of 77 hematology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 123 | $1,936,630 |
| CerdelgaEliglustat Tartrate | 16 | $493,281 |
| DopteletAvatrombopag Maleate | 23 | $429,720 |
| ImbruvicaIbrutinib | 34 | $419,597 |
| EliquisApixaban | 96 | $129,876 |
| XareltoRivaroxaban | 72 | $95,830 |
| RetacritEpoetin Alfa-Epbx | 12 | $41,193 |
| Fondaparinux Sodium | 19 | $24,697 |
| Hydroxyurea | 135 | $4,647 |
| Prednisone | 27 | $444 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $2,460 | $1,936,630123 claims |
| SanofiCerdelga | $109,709 | $493,28116 claims |
| Dova PharmaceuticalsDoptelet | $26,547 | $429,72023 claims |
| PfizerEliquis, Retacrit | $4,500 | $171,070108 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 77 hematology providers in Massachusetts.
Other hematology in Boston
- Edward BenzBoston$747K
- Jacalyn RosenblattBoston$455K
- Lynn BryBoston$286K
- John SloanBoston$257K
- Andrew EvensBoston$217K
- Omar NadeemBoston$191K
- Nathan ConnellBoston$145K
- Jean ConnorsBoston$144K
- Heather BenjaminBoston$106K
- Martin SteinbergBoston$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.